Also

U.S. states objected to a plan by Bristol-Myers Squibb Co. and Sanofi-Aventis to keep a generic copy of their top-selling blood thinner Plavix off the market, reviving a dispute over the product’s patent. Attorneys general representing the 50 states had sued Bristol-Myers Squibb on allegations that it misused patents to thwart low-cost rivals.